NEWS RELEASE

New European Project Squares Off Against Paediatric Cancer

The iPC project is now underway and bringing hope to children with cancer

January, 2019

Cancer in children is rare but when it happens, clinically prescribed treatment options are not always as efficient as one would hope. Of those that are cured, a substantial proportion suffer long-term serious health consequences from the intensive treatments that are currently required. A major reason for cancer being so difficult to treat effectively is that cancer cells undergo many random changes, which means that each cancer has an essentially unique combination of molecular characteristics. To address this problem, it is important to develop ways of specifically tailoring treatment combinations for the molecular profile of each individual cancer, to maximize cures and to minimize short- and long-term treatment side-effects.

Under the technical leadership of Dr. María Rodíguez Martínez from IBM in Switzerland and the coordination of the Austrian-based private research company Technikon, consortium scientists have recently kicked off a European Commission funded research project entitled iPC (individualizedPaediatricCure). In this € 15 million, four-year endeavor, 21 partners from eleven different countries, including nine European Union Member States (Austria, Belgium, Switzerland, Germany, Spain, France, Italy, Netherlands, Slovenia), along with the USA and Australia will work together with the goal of giving clinicians the tools and knowledge to create individualized treatment plans to children with cancer. The project team will focus on identifying effective personalized medicine for paediatric cancers and will address a multitude of challenges. To meet these challenges, a comprehensive computational effort to combine knowledge-base, machine-learning, and mechanistic models to predict optimal standard and experimental therapies for each child will be proposed.

The goal of the iPC project is to collect, standardize and harmonize existing clinical knowledge and medical data and, with the help of artificial intelligence, create treatment models for each patient. Armed with these treatment models, scientists will then test them on virtual patients to evaluate treatment efficacy and toxicity, thus improving both patient survival and their quality of life.

While the ever-present complexities of cancer continue to challenge our scientific community, it is reassuring that European projects like iPC are using the latest technology and brightest minds to find solutions which, in turn, usher in better patient care. In summary, iPC will address the critical need for personalized medicine for children with cancer, contribute to the digitalization of clinical workflows, and enable the Digital Single Market of the EU data infrastructure.

The iPC partners are

- TECHNIKON FORSCHUNGS- UND PLANUNGSGESELLSCHAFT mbH (Austria)
- IBM RESEARCH GMBH (Switzerland)
Contact information:

**Project Coordinator:**
Dr. Klaus-Michael Koch  
TECHNIKON Forschungs- und Planungsgesellschaft mbH  
Burgplatz 3a  
9500 Villach  
Austria  
E-Mail: coordination@IPC-project.eu

**Technical Lead:**
María Rodríguez Martínez  
IBM Research - Zurich  
Säumerstrasse 4  
8803 Rüschlikon  
Switzerland  
E-Mail: MRM@zurich.ibm.com

*The iPC project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 826121.*